Key result
Spironolactone use in ideal post-AMI patients in China rises to ~72%, alongside increased contraindicated use.
Why the study?
How frequently was eligibility for in-hospital spironolactone assessed and how did utilization patterns change from 2001 to 2011 among patients hospitalized for acute myocardial infarction with heart failure or diabetes in China?
Cohort (n=6,906)
Yes
How frequently was eligibility for in-hospital spironolactone assessed and how did utilization patterns change from 2001 to 2011 among patients hospitalized for acute myocardial infarction with heart failure or diabetes in China?
In China between 2001 and 2011, in-hospital spironolactone use and LVEF assessment post-AMI increased substantially among ideal candidates, but inappropriate use in contraindicated and non-indicated patients also rose, highlighting major gaps in evidence translation and patient selection.
Answers are grounded in this paper and cite their sources.
Increased inappropriate spironolactone use in contraindicated AMI patients raises safety concerns; leaves open optimal implementation of eligibility criteria.
BACKGROUND: Spironolactone, the only aldosterone antagonist available in China, improves outcomes in acute myocardial infarction (AMI) among patients with systolic dysfunction and either diabetes or heart failure (HF). However, national practice patterns in the use of spironolactone in China are unknown. METHODS AND RESULTS: From a nationally representative sample of AMI patients from in 2001, 2006, and 2011, we identified 6906 patients with either diabetes or HF and classified them into 1 of 4 groups according to their eligibility for spironolactone-"ideal"(left ventricular ejection fraction [LVEF] ≤40% and without contraindications), "contraindicated," "not indicated" (neither ideal nor contraindicated), and "unknown indications" (LVEF unmeasured)-to determine how frequently patient eligibility for this drug is assessed in the hospital, how it is used in several groups, and to identify factors associated with the use in these groups. From 2001 to 2011, the proportion of patients whose eligibility for spironolactone was not assessed decreased (66.9% in 2001 to 32.8% in 2011). Spironolactone use significantly increased among ideal patients over this period (28.6% to 72.4%; P<0.001 for trend), but also in contraindicated patients (11.4% to 27.5%; P=0.002 for trend) and in other patients groups (not indicated: 27.5% to 38.3%; unknown indications: 21.3% to 35.1%; both P<0.01 for trend). In all 4 groups, patients presenting with HF on admission were more likely to receive spironolactone. CONCLUSIONS: Although the appropriate use of spironolactone and assessment of eligibility increased in China over the past decade, there remains marked opportunities for improvement. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov Unique identifier: NCT01624883.
No takes yet. Share an insight, caveat, or question.
Guan et al. (2015) conducted a cohort in Acute myocardial infarction with heart failure or diabetes (n=6,906). Spironolactone eligibility and temporal era (2011 vs 2001) vs. 2001 baseline cohort and non-ideal eligibility groups (contraindicated, not indicated, unknown indications) was evaluated on Weighted rate of in-hospital spironolactone use among ideal patients (LVEF <=40% without contraindications) from 2001 to 2011 (p=<0.001 for trend). Spironolactone use among ideal AMI patients in China increased from 28.6% in 2001 to 72.4% in 2011, alongside increased use in contraindicated patients.
Synapse has enriched 10 related papers. Consider them for comparative context: